Should We Embark on "EMBARK"? Reassessing the Role of Radiotherapy and Androgen Receptor Pathway Inhibitors in the Era of Next-generation Imaging.

Marvaso G; Francolini G; Achard V; Gomez-Iturriaga A; Slevin F; Zilli T; Ost P

doi:10.1016/j.eururo.2025.08.020

← 뒤로

Should We Embark on "EMBARK"? Reassessing the Role of Radiotherapy and Androgen Receptor Pathway Inhibitors in the Era of Next-generation Imaging.

European urology 2026 Vol.89(1) p. 5-7

Marvaso G, Francolini G, Achard V, Gomez-Iturriaga A, Slevin F, Zilli T, Ost P

원문 ↗ DOI ↗ BibTeX ↓ RIS ↓

📝 환자 설명용 한 줄

Results from the EMBARK trial reshape the treatment paradigm for high-risk biochemical recurrence of prostate cancer.

이 논문을 인용하기

BibTeX ↓ RIS ↓

APA Marvaso G, Francolini G, et al. (2026). Should We Embark on "EMBARK"? Reassessing the Role of Radiotherapy and Androgen Receptor Pathway Inhibitors in the Era of Next-generation Imaging.. European urology, 89(1), 5-7. https://doi.org/10.1016/j.eururo.2025.08.020

MLA Marvaso G, et al.. "Should We Embark on "EMBARK"? Reassessing the Role of Radiotherapy and Androgen Receptor Pathway Inhibitors in the Era of Next-generation Imaging.." European urology, vol. 89, no. 1, 2026, pp. 5-7.

PMID 40947367

DOI 10.1016/j.eururo.2025.08.020

Abstract

Results from the EMBARK trial reshape the treatment paradigm for high-risk biochemical recurrence of prostate cancer. EMBARK data support the use of androgen receptor pathway inhibitors combined with metastasis-directed therapy in a personalized, multidisciplinary care approach for this subset of patients.

MeSH Terms

Humans; Male; Prostatic Neoplasms; Androgen Receptor Antagonists; Neoplasm Recurrence, Local; Receptors, Androgen; Androgen Antagonists